Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 4Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × JDQ443 × Clear all
NCT05132075 2026-06-02

KontRASt-02

Novartis

Phase 3 Active not recruiting
95 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05445843 2026-05-14

KontRASt-06

Novartis

Phase 2 Active not recruiting
95 enrolled 20 charts
Thoracic

Lung Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Novartis

Phase 1/2 Active not recruiting
74 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07468071 2026-04-02

KontRASt-R

Novartis

Phase 1/2 Not yet recruiting
40 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04699188 2026-03-18

KontRASt-01

Novartis

Phase 1/2 Active not recruiting
344 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05329623 2025-10-10

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Novartis

Phase 1 Completed
33 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡